AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29040638
Drug: Serum progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Serum progesterone < 9.2 ng/ml
Trial: 29040638
Drug: Serum progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Serum progesterone ≥ 9.2 ng/ml
Trial: 29040638
Drug: Logistic regression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistic regression analysis for serum P < 9.2 ng/ml
Trial: 29041979
Drug: Anti-tumor necrosis
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tumor necrosis factor (anti-TNF) treatment with or without MTX
Trial: 29042364
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy with genetically modified T cells
Trial: 29043014
Drug: Lanadelumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab (300 mg subcutaneously) administered every 2 weeks after an initial dose on Day 0 and after the first confirmed angioedema attack for rollover patients.
Trial: 29043014
Drug: Lanadelumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab (300 mg subcutaneously) administered every 2 weeks for non-rollover patients regardless of the first attack.
Trial: 29045037
Drug: Anti-ficolin-2 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-ficolin-2 antibodies in SLE patients
Trial: 29045037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti-ficolin-2, anti-ficolin-3, and anti-C1q
Trial: 29045540
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg i.v. Q3weeks until disease progression
Trial: 29045543
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and trastuzumab (and hormonal therapy if HR-positive) for 18 weeks
Trial: 29045739
Drug: 0.50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg/kg bodyweight ketamine administered once i.v.
Trial: 29046319
Drug: Intravenous Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Fentanyl
Trial: 29047411
Drug: Lactate level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate level > 1.5 mmol/L
Trial: 29047411
Drug: Mildly elevated
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly elevated lactate levels (1-2 mmol/L)
Trial: 29049861
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) followed by Misoprostol (800 μg buccal) after 24 hours
Trial: 29051021
Drug: Nilotinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (200 mg dose identified as maximum tolerated dose)
Trial: 29051021
Drug: Nilotinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (200 mg dose)
Trial: 29051021
Drug: Pretreatment anti-PDGFRA
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment anti-PDGFRA antibody levels ≥ .150 optical density
Trial: 29051134
Drug: Video-based telerehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-based telerehabilitation intervention (8 weekly, 1-hour sessions)
Trial: 29053802
Drug: DHA (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (800 mg, algal oil) daily from 26 weeks to term
Trial: 29053802
Drug: Placebo (corn/soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn/soy oil) daily from 26 weeks to term
Trial: 29055637
Drug: Normal Glucose
RxNorm normalized name: Normal Glucose Control Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Glucose Metabolism (NGM)
Trial: 29055736
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT lung cancer screening
Trial: 29056570
Drug: AZD3759 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3759 at 200 mg twice a day
Trial: 29056570
Drug: AZD3759 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3759 at 300 mg twice a day
Trial: 29057117
Drug: Triple fixed-combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC)
Trial: 29057117
Drug: Dual fixed-combination
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC)
Trial: 29058601
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of meropenem
Trial: 29058816
Drug: Oral bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral bosutinib (100 mg × 5)
Trial: 29058816
Drug: Intravenous bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous bosutinib (120 mg in approximately 240 mL over 1 hour)
Trial: 29062240
Drug: Oliceridine regimen
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oliceridine regimen A (1.5/0.10 mg)
Trial: 29062240
Drug: Oliceridine regimen
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oliceridine regimen B (1.5/0.35 mg)
Trial: 29062240
Drug: Morphine (4.0/1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (4.0/1.0 mg)
Trial: 29064349
Drug: Bosentan monotherapy
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan monotherapy for 16 weeks
Trial: 29064927
Drug: Rectal distension
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal distension stimulations in patients with IBS
Trial: 29064927
Drug: Rectal distension
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal distension stimulations in healthy controls
Trial: 29065747
Drug: Intravenous melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous melphalan
Trial: 29065865
Drug: Exenatide 5
RxNorm normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 5 to 10 μg twice a day for 20 weeks
Trial: 29066505
Drug: Pan-AKT Inhibitor
RxNorm normalized name: Pan-raf inhibitor lxh254
DrugBank: Naporafenib (DB18865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pan-AKT Inhibitor AZD5363
Trial: 29066590
Drug: Home Pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Pulmonary Rehabilitation (PR) program including a computer tablet, activity monitor, and oximeter, with 12 min of walking and 6 full-body exercises, completed 6 days/week, plus weekly telephone calls with the PR health coach.
Trial: 29067298
Drug: Bexarotene (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexarotene (oral administration for 3 days)
Trial: 29067298
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral administration for 3 days)
Trial: 29067304
Drug: Aducanumab (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (0.3, 1, 3, 10, 20, 30, and 60 mg/kg)
Trial: 29067332
Drug: UB-311 (synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UB-311 (synthetic peptide vaccine)
Trial: 29067643
Drug: Gedatolisib (PF-05212384)
RxNorm normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gedatolisib (PF-05212384) with Irinotecan 180 mg/m
Trial: 29068794
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (50-300 mg/day) as monotherapy or adjunctive therapy
Trial: 29068794
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (higher than recommended doses)
Trial: 29068794
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR as adjunctive therapy to antidepressants
Trial: 29069114
Drug: Concomitant calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant calcium channel blocker (CCB) plus antipsychotic (AP) therapy
Trial: 29069114
Drug: Antipsychotic (AP)
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic (AP) therapy alone
Trial: 29070010
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg twice-daily for 1 year
Trial: 29070480
Drug: Internet-delivered dialectical
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered dialectical behavior therapy (DBT) skills training, 8-week intervention
Trial: 29070939
Drug: palucorcel (CNTO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palucorcel (CNTO 2476) administered subretinally at a targeted dose of 3.0×10
Trial: 29071072
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy (HFNT) during exercise tests
Trial: 29071087
Drug: DS-8500a 10
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8500a 10 mg
Trial: 29071091
Drug: RenalGuard system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RenalGuard system with weight-adjusted intravenous furosemide
Trial: 29072772
Drug: Bosutinib treatment
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib treatment in CP2L cohort
Trial: 29072772
Drug: Bosutinib treatment
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib treatment in CP3L cohort
Trial: 29073362
Drug: Early implant
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early implant placement with simultaneous contour augmentation through guided bone regeneration with a 2-layer composite graft
Trial: 29073584
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg/d
Trial: 29074501
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/d until progression or intolerance
Trial: 29075620
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs), specific dosage and duration not mentioned.
Trial: 29075855
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatuxizumab mafodotin (depatux-m) monotherapy at 1.25 mg/kg intravenously every 2 weeks
Trial: 29077645
Drug: Diet Rite
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet Rite Cola, sweetened with 68-mg sucralose and 41-mg ace-K
Trial: 29077963
Drug: Movement System
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement System Impairment-Based Classification Treatment
Trial: 29078273
Drug: Bevacizumab (anti-VEGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (anti-VEGF drug)
Trial: 29078773
Drug: Anti-malarial treatment
RxNorm normalized name: malarial plasmodium group immunoserum rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-malarial treatment
Trial: 29079633
Drug: Severe persistent
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe persistent hyponatraemia (serum sodium <130 mmol/L)
Trial: 29079658
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin I (hs-cTnI) measurements using Abbott assay, sex-specific 99th percentiles (women, 16 ng/L; men, 34 ng/L)
Trial: 29079987
Drug: Novel DGP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel DGP treatment (specifics not provided)
Trial: 29080061
Drug: Chemotherapy (CTh+)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CTh+)
Trial: 29080915
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg triamcinolone
Trial: 29080970
Drug: Ibrutinib 1680
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 1680 mg
Trial: 29081368
Drug: JE-CV (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV (single dose)
Trial: 29082335
Drug: Daily 12-lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 12-lead ECG once daily for 5 days
Trial: 29082650
Drug: Telbivudine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine therapy throughout pregnancy
Trial: 29084869
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous immunoglobulin treatment
Trial: 29086392
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydralazine and isosorbide dinitrate (Hy+ISDN)
Trial: 29087741
Drug: Long-term supplemental
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term supplemental oxygen treatment
Trial: 29089191
Drug: Quadrivalent live
RxNorm normalized name: influenza vaccine quadrivalent live 2015-2016 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent live attenuated influenza vaccine (LAIV4) or inactivated influenza vaccine (IIV4)
Trial: 29090343
Drug: Non-intensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intensive treatment or best supportive care
Trial: 29091557
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of adeno-associated virus serotype 9 carrying SMN complementary DNA
Trial: 29091557
Drug: High-dose cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cohort of adeno-associated virus serotype 9
Trial: 29092017
Drug: Conservative compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conservative compression treatment
Trial: 29093819
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy (DBT) adapted for Adolescents
Trial: 29095983
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g twice daily) for 9.4 to 13.7 weeks
Trial: 29096647
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to HCV medical treatment for HCV-positive patients
Trial: 29096668
Drug: Lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide plus other treatment
Trial: 29096668
Drug: Overall response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Overall response rate to lenalidomide-based therapy
Trial: 29096668
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events after lenalidomide-containing therapy
Trial: 29096670
Drug: E/C/F/TDF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TDF plus darunavir 800 mg daily
Trial: 29096790
Drug: Mean on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mean on-treatment BP (systolic and diastolic)
Trial: 29097417
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with HIV in care with viral loads >1500 copies/mL
Trial: 29097417
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with HIV in care with high viral loads and concurrent risk behaviour
Trial: 29098088
Drug: Dilute (3%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute (3%) povidone-iodine solution through a low-pressure pulsatile device
Trial: 29098088
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution through a bulb syringe
Trial: 29098299
Drug: Bioabsorbable steroid-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable steroid-releasing implant (370 µg of mometasone furoate) placed in the frontal sinus ostia (FSO) after endoscopic sinus surgery (ESS)
Trial: 29098299
Drug: Bioabsorbable steroid-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable steroid-releasing implant
Trial: 29099942
Drug: High-specific-activity I-131
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-specific-activity I-131 meta-iodobenzylguanidine (MIBG) therapy at a maximum tolerated dose (MTD) of 296 MBq/kg.
Trial: 29099942
Drug: High-specific-activity I-131
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-specific-activity I-131 MIBG therapy
Trial: 31334596
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg every 3 weeks
Trial: 31334596
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg every 3 weeks
Trial: 29100412
Drug: Bromocriptine (7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (7.5mg daily) added to spironolactone
Trial: 29101463
Drug: Dovitinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib (300 mg in 5 days on/2 days off schedule) with fluvoxamine
Trial: 29101463
Drug: Dovitinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib (300 mg in 5 days on/2 days off schedule) without fluvoxamine
Trial: 29103916
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + Torcetrapib
Trial: 29103916
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + Placebo
Trial: 29107441
Drug: Hydroxyurea, median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea, median treatment duration 7 years, mean therapeutic dose 18±4.7 mg/kg/day
Trial: 29107621
Drug: Single-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose azithromycin (30 mg/kg)
Trial: 29109077
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of mRNA-transfected c-Met-CAR T cells (3 × 10^6 cells)
Trial: 29110152
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus trastuzumab (plus endocrine therapy for ER-positive tumors)
Trial: 29110849
Drug: Afatinib monotherapy
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib monotherapy (40mg daily)
Trial: 29110849
Drug: Afatinib plus
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib plus cetuximab (afatinib 40mg daily + cetuximab 500mg/m)
Trial: 29110849
Drug: Afatinib plus
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib plus cetuximab for patients who received afatinib monotherapy for ≥12 weeks
Trial: 29110849
Drug: Afatinib plus
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib plus cetuximab for patients who received afatinib monotherapy for <12 weeks
Trial: 29111011
Drug: Natalizumab therapy
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab therapy
Trial: 29112634
Drug: Therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with sympathomimetic drugs and fluid therapy
Trial: 29112650
Drug: 1,500-mL intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500-mL intravenous fluid bolus
Trial: 29112650
Drug: 500-mL intravenous
RxNorm normalized name: lifileucel
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mL intravenous fluid bolus